FDA to Use Ariana's Data-Mining Tool to Analyze Gene Targets in VXDS Program

Ariana Pharma announced this week that the FDA will use its KEM Biomarker technology to "systematically identify potential genomic 'fingerprints' and develop recommendations for the analysis of genomic data prior to submission of biomarker signatures."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories